PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22147632-0	2012	The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells.	tofacitinib	18-29	interleukin 17A	Homo sapiens	93-107	
22147632-5	2012	RESULTS: Tofacitinib treatment of CD4+ T cells originating from synovium and peripheral blood inhibited the production of interleukin-17 (IL-17) and interferon-gamma (IFNgamma) in a dose-dependent manner, affecting both proliferation and transcription, but had no effect on IL-6 and IL-8 production.	tofacitinib	9-20	interleukin 17A	Homo sapiens	122-136	
22147632-5	2012	RESULTS: Tofacitinib treatment of CD4+ T cells originating from synovium and peripheral blood inhibited the production of interleukin-17 (IL-17) and interferon-gamma (IFNgamma) in a dose-dependent manner, affecting both proliferation and transcription, but had no effect on IL-6 and IL-8 production.	tofacitinib	9-20	interleukin 17A	Homo sapiens	138-143	
22147632-9	2012	CONCLUSION: Tofacitinib directly suppressed the production of IL-17 and IFNgamma and the proliferation of CD4+ T cells, resulting in inhibition of IL-6 production by RASFs and IL-8 production by CD14+ cells and decreased cartilage destruction.	tofacitinib	12-23	interleukin 17A	Homo sapiens	62-80